Tags

Type your tag names separated by a space and hit enter

Treatment of skeletal disease in breast cancer: a controlled clodronate trial.
Bone. 1987; 8 Suppl 1:S53-6.BONE

Abstract

Normocalcaemic breast cancer patients with progressive osteolytic bone metastases were treated with clodronate 1.6 g/day (17) or placebo (17) for 12 months. Bone pain, extension of bone metastases and formation of new osteolytic foci were reduced by clodronate, and development of severe hypercalcaemia was prevented. After withdrawal of treatment the patients were followed-up for at at least 12 months. New bone metastases developed in both groups. There were, however, less fractures and less hypercalcaemia in the clodronate than in the placebo group. The survival rate was higher in the clodronate group than in the placebo group. No haematological toxicity was observed in the clodronate group.

Authors+Show Affiliations

Department of Radiotherapy, University of Helsinki, Finland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

2961355

Citation

Elomaa, I, et al. "Treatment of Skeletal Disease in Breast Cancer: a Controlled Clodronate Trial." Bone, vol. 8 Suppl 1, 1987, pp. S53-6.
Elomaa I, Blomqvist C, Porkka L, et al. Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone. 1987;8 Suppl 1:S53-6.
Elomaa, I., Blomqvist, C., Porkka, L., Lamberg-Allardt, C., & Borgström, G. H. (1987). Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone, 8 Suppl 1, S53-6.
Elomaa I, et al. Treatment of Skeletal Disease in Breast Cancer: a Controlled Clodronate Trial. Bone. 1987;8 Suppl 1:S53-6. PubMed PMID: 2961355.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of skeletal disease in breast cancer: a controlled clodronate trial. AU - Elomaa,I, AU - Blomqvist,C, AU - Porkka,L, AU - Lamberg-Allardt,C, AU - Borgström,G H, PY - 1987/1/1/pubmed PY - 1987/1/1/medline PY - 1987/1/1/entrez SP - S53 EP - 6 JF - Bone JO - Bone VL - 8 Suppl 1 N2 - Normocalcaemic breast cancer patients with progressive osteolytic bone metastases were treated with clodronate 1.6 g/day (17) or placebo (17) for 12 months. Bone pain, extension of bone metastases and formation of new osteolytic foci were reduced by clodronate, and development of severe hypercalcaemia was prevented. After withdrawal of treatment the patients were followed-up for at at least 12 months. New bone metastases developed in both groups. There were, however, less fractures and less hypercalcaemia in the clodronate than in the placebo group. The survival rate was higher in the clodronate group than in the placebo group. No haematological toxicity was observed in the clodronate group. SN - 8756-3282 UR - https://www.unboundmedicine.com/medline/citation/2961355/Treatment_of_skeletal_disease_in_breast_cancer:_a_controlled_clodronate_trial_ L2 - https://ClinicalTrials.gov/search/term=2961355 [PUBMED-IDS] DB - PRIME DP - Unbound Medicine ER -